Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Krina K. Patel, MDMSc, Jatin J. Shah, MD, Lei Feng, MS, Hans C. Lee, MD, Elisabet E. Manasanch, MD, Sheeba K. Thomas, MD, Donna M. Weber, MD, Silvia C. Munoz, RN, Ashley Morphey, RN, Qaiser Bashir, MD MBBS, Muzaffar H. Qazilbash, MD, Robert Z. Orlowski, MD PhD

Blood (2017) 130 (Supplement 1): 437.

https://doi.org/10.1182/blood.V130.Suppl_1.437.437

Published: 2017

Journal Articles

Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma

Elisabet E. Manasanch, MD, Rohit Mathur, PhD, Hans C. Lee, MD, Donna M. Weber, MD, Krina K. Patel, MDMSc, Sheeba K. Thomas, MD, Silvia C. Munoz, RN, Claudia Morales de Partovi, Catherine M. Claussen, MS, Pei Lin, MDDM,MDC, Behrang Amini, MD, Linghua Wang, Man Chun John MA, PhD, Yun Qing, Feng Lei, MS, Veera Baladandayuthapani, PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD, Robert Z. Orlowski, MD PhD

Blood (2017) 130 (Supplement 1): 3089.

https://doi.org/10.1182/blood.V130.Suppl_1.3089.3089

Published: 2017

Journal Articles

Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Jatin J. Shah, MD, Lei Feng, MS, Donna Weber, MD, Sheeba K Thomas, MD, Michael Wang, MD, Francesco Turturro, MD, Muzaffar H. Qazilbash, MD, Nina Shah, MD, Qaiser Bashir, MD, Uday R. Popat, MD, Elisabet E. Manasanch, MD, Silvia C Munoz, RN, Ashley Landry, RN, Kathleen Mendoza, RN, Yago Nieto, MD PhD, Richard E. Champlin, MD, Robert Z. Orlowski, PhD, MD

Blood (2015) 126 (23): 3155.

https://doi.org/10.1182/blood.V126.23.3155.3155

Published: 2015

Journal Articles

Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

Jatin J. Shah, MD, Lei Feng, MS, Elisabet E. Manasanch, MD, Donna Weber, MD, Sheeba K Thomas, MD, Francesco Turturro, MD, Nina Shah, MD, Uday R. Popat, MD, Yago Nieto, MD PhD, Qaiser Bashir, MD, Silvia C Munoz, RN, Ashley Landry, RN, Kathleen Mendoza, RN, Richard E. Champlin, MD, Muzaffar H. Qazilbash, MD, Robert Z. Orlowski, PhD, MD

Blood (2015) 126 (23): 187.

https://doi.org/10.1182/blood.V126.23.187.187

Published: 2015

Journal Articles

Pyrrolidine dithiocarbamate inhibits the production of interleukin-6, interleukin-8, and granulocyte-macrophage colony-stimulating factor by human endothelial cells in response to inflammatory mediators: modulation of NF-kappa B and AP-1 transcription factors activity

C Munoz, D Pascual-Salcedo, MC Castellanos, A Alfranca, J Aragones, A Vara, MJ Redondo, MO de Landazuri

Blood (1996) 88 (9): 3482–3490.

https://doi.org/10.1182/blood.V88.9.3482.bloodjournal8893482

Published: 1996

NARROW

Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma

Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

Pyrrolidine dithiocarbamate inhibits the production of interleukin-6, interleukin-8, and granulocyte-macrophage colony-stimulating factor by human endothelial cells in response to inflammatory mediators: modulation of NF-kappa B and AP-1 transcription factors activity

Email alerts

ASH Publications

American Society of Hematology

Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma

Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

Pyrrolidine dithiocarbamate inhibits the production of interleukin-6, interleukin-8, and granulocyte-macrophage colony-stimulating factor by human endothelial cells in response to inflammatory mediators: modulation of NF-kappa B and AP-1 transcription factors activity

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only